KetamineOne Capital (NEO: MEDI) appears to be taking a rather novel approach to psychedelic treatments. The firm this morning revealed that it has signed an exclusive agreement to bring virtual reality to the treatment options the firm provides, with the tech further enhanced by providing an “olfactory-enabled” experience.
The agreement itself is with that of OVR Tech LLC, and is for an initial term of two years. The arrangement will see OVR Tech’s virtual reality technology, which is further enhanced with smells, to KetamineOne’s psychedelic treatments that involve DMT, MDMA, psilocybin and ketamine.
Referred to as the INHALE Wellness Platform, the head mounted display tech includes scent cartridges to enhance the user experience. The addition of the olfactory sense is expected to provide a deeper level of immersion, manage stress, and promote enhanced relaxation.
Sponsored · Antimony Resources
Commenting on the additional of VR to the firms clinical playbook, Ketamine One’s Chair of its Clinic Innovation Council, Dr Quang Henderson, commented, “We believe that the ION device contains the most accurate on-mask scent technology currently available on the market. The ability for our clinicians to alter perceptual experiences with VR and the ION is extremely promising. Optimizing the therapeutic setting is one of the main goals of our VR-based research and development program and being able to utilize the sense of smell to help patients relax, reduce tension and lower stress is expected to result in the development of a comprehensive treatment.“
KetamineOne Capital last traded at $1.44 on the Neo.
FULL DISCLOSURE: KetamineOne is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover KetamineOne on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
